Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 306-084-8 | CAS number: 95912-88-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 16 Nov 1982 - 19 Jan 1983
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Meets generally accepted scientific principles, well documented and sufficient for assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1987
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Decyl oleate
- EC Number:
- 222-981-6
- EC Name:
- Decyl oleate
- Cas Number:
- 3687-46-5
- Molecular formula:
- C28H54O2
- IUPAC Name:
- decyl octadec-9-enoate
- Details on test material:
- - Name of test material (as cited in study report): Oelsaeuredecylester
- Physical state: light yellow, clear, oily liquid
- Analytical purity: no data given
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Wistar Han
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Zentralinstitut fuer Versuchstiere, Hannover, Germany
- Age at study initiation: approx. 4 months
- Weight at study initiation: males: 50-81 g; females: 50-82 g
- Housing: 2-3 animals per cage in macrolon cages type III
- Diet: Altromin 1324 DK pelleted diet (Altromin GmbH, Lage, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature: 21-22 °C
- Humidity: 49-65 %
- Photoperiod: 12 hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- The test material was administered once daily by gavage for five days per week. The control animals were treated in the same way with the respective vehicle only (olive oil; 5 ml/kg bw/d). The dosing solution were prepared daily prior to administration. The application volumes were adopted weekly to the current body weights.
- Duration of treatment / exposure:
- 28 days (21 applications)
- Frequency of treatment:
- once daily on five days per week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 100 (2%), 500 (10%) and 1000 (20%) mg/kg bw/d (groups 1-4)
Basis:
actual ingested
- No. of animals per sex per dose:
- 10 animals per sex per dose, treated with 21 applications and sacrificed after 28 days
5 animals per sex per sex per dose, treated with 21 applications and remained untreated thereafter for further 28 days (recovery group) - Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- All animals were observed daily. The body weight was measured weekly and served as main parameter for the actual health status of the animals. Food and water consumption was determined weekly.
At the end of the study period, urine and feces examinations were conducted.
For haematological examinations, the blood was collected from the orbital plexus during a temporary ether anaesthesia of the animals. The following clinico-chemical parameters were examined:
- Blood: Haematokrit, haemoglobin content, red and white blood cell count, mean cell volume, thrombocyte cell count, differential blood count.
- Enzymes and subtrates in serum: Kidney profile: urea, creatinine, sodium and potassium; adrenal profile: glucose, sodium and potassium; mineral metabolism and parathyroid profile: calcium, inorganic phosphor and alkaline phosphatase; electrolyte profile: sodium, potassium, chloride, albumin, total protein; thyroid profile: cholesterol. - Sacrifice and pathology:
- During the section, the absolute and relative weight of the following organs was determined: thyroid, adrenals, thymus, spleen, heart, kidneys, brain, testes and liver.
Gross pathology was conducted with all animals. Additionally, 10 male and 10 female animals of the main test groups (1-4) were also examined histopathologically. The target of the main groups (1-4) was the liver which was examined in 3 male and 3 female animals; in the recovery groups (1-4), the target organs were lungs, pancreas, axillary lymph node, salivary gland and forestomach.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Details on results:
- All doses were tolerated in all test animals without test material related mortality or symptoms of intoxication.
Food and water consumption and development of body weight yielded no substance-related deviations during the course of the study in comparison to the control.
A slightly decreased haemoglobin value in the blood of all test groups and slightly decreased phosphorous values in the serum of selected test groups were considered to be not related to treatment.
The examination of urine was without relevant findings, only in one female of test group 4, eggs from parasitic origin were detected. Feces amount was reduced in female animals of group 2 and 4, the appearance of the feces was as expected.
The examination of the eyes revealed no substance related findings.
The absolute and relative organ weights revealed no dose related findings.
The gross section of all animals and the microscopic examination of the high dose and control animals revealed no substance related alterations of inner organs. In some cases, spontaneous findings were noted: Histopathologically, there were some findings in the salivary glands, axillary lymph nodes, pancreas and lungs which were caused by virus infections. The cutaneous mucosa of the forestomach showed either degenerative changes or signs of inflammation. These effects were seen in the test groups, as well as in the controls. Furthermore, changes of the glands in fundus and pylorus were also seen in both treated- and control animals.
For further details on the results obtained, see table 1 in "Remarks on results ...".
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: overall effects: No adverse effect on clinical signs; mortality; body weight; haematology; gross pathology and histopathology.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Data of selected parameters determined in the study, which reached statistical significance at least in one value:
food consumption (g/animal/d), group mean values |
|
|
|
|
||||
week |
group, sex (m/f) |
|
|
|
|
|
|
|
|
1 m |
2 m |
3 m |
4 m |
1 f |
2 f |
3 f |
4 f |
1 |
18 |
16 |
18 |
18 |
14 |
15 |
14 |
15 |
2 |
19 |
18 |
21** |
22** |
14 |
14 |
15** |
16* |
3 |
22 |
21 |
21 |
21* |
16 |
17 |
15 |
16 |
4 |
17 |
17 |
19 |
19 |
13 |
13 |
13 |
14 |
water consumption (ml/animal/d), group mean values |
|
|
|
|
||||
week |
group, sex (m/f) |
|
|
|
|
|
|
|
|
1 m |
2 m |
3 m |
4 m |
1 f |
2 f |
3 f |
4 f |
1 |
29 |
25* |
27 |
29 |
27 |
24 |
24 |
24 |
2 |
28 |
25** |
30 |
31* |
28 |
22** |
26 |
27 |
3 |
33 |
29 |
30 |
30 |
32 |
27 |
26* |
25* |
4 |
30 |
25 |
27 |
29 |
29 |
28 |
24* |
24 |
body weights and weight gain (g) |
|
|
|
|
|
|
||
week |
group, sex (m/f) |
|
|
|
|
|
|
|
|
1 m |
2 m |
3 m |
4 m |
1 f |
2 f |
3 f |
4 f |
0 |
67 |
60* |
64 |
67 |
64 |
63 |
60 |
63 |
1 |
107 |
96** |
105 |
108 |
96 |
96 |
94 |
95 |
2 |
147 |
137 |
147 |
150 |
123 |
124 |
122 |
124 |
3 |
189 |
178 |
191 |
196 |
146 |
147 |
146 |
147 |
4 |
220 |
208 |
227 |
229 |
161 |
162 |
163 |
173 |
gain week 0-4 |
153 |
148 |
163 |
162 |
97 |
99 |
103 |
110 |
selected haematology parameters (after week 4) |
|
|
|
|
|
|||
|
group, sex (m/f) |
|
|
|
|
|
|
|
|
1 m |
2 m |
3 m |
4 m |
1 f |
2 f |
3 f |
4 f |
haemoglobin (Hb) mmol/l |
10.9 |
10.1 |
9.9** |
9.8** |
10.6 |
9.9** |
9.9** |
9.8** |
red blood cell count (RBC) T/l |
7.2 |
6.9 |
6.6 |
6.8 |
6.9 |
6.4 |
6.0* |
6.5 |
haematokrit (HAT) l/l |
0.39 |
0.38 |
0.36 |
0.37 |
0.36 |
0.34 |
0.32** |
0.35 |
alkaline phosphatase (AP) U/l |
371 |
356 |
390 |
361 |
247 |
211 |
196* |
206 |
inorganic phosphate |
3.1 |
2.9* |
2.7** |
2.8* |
2.6 |
2.4* |
2.4 |
2.5 |
organ weights after 4 weeks |
|
|
|
|
|
|
||
|
group, sex (m/f) |
|
|
|
|
|
|
|
|
1 m |
2 m |
3 m |
4 m |
1 f |
2 f |
3 f |
4 f |
thyroid absolute (mg) |
25 |
22* |
23 |
23 |
21 |
23 |
19 |
22 |
spleen absolute (g) |
0.57 |
0.59 |
0.63* |
0.63 |
0.46 |
0.45 |
0.46 |
0.46 |
heart absolute (g) |
0.80 |
0.73* |
0.78 |
0.80 |
0.61 |
0.61 |
0.58 |
0.64 |
kidney absolute (g) |
1.66 |
1.58 |
1.73 |
1.80 |
1.19 |
1.22 |
1.19 |
1.28* |
thyroid relative (% of body weight) |
0.010 |
0.010 |
0.009* |
0.009 |
0.013 |
0.014 |
0.011 |
0.013 |
adrenal relative (% of body weight) |
0.025 |
0.025 |
0.024 |
0.025 |
0.046 |
0.044 |
0.039* |
0.045 |
heart relative (% of body weight) |
0.33 |
0.32 |
0.31** |
0.31* |
0.36 |
0.36 |
0.34 |
0.37 |
* = level of significance 95% in comparison with control value
** = level of significance 99% in comparison with control value
Applicant's summary and conclusion
- Conclusions:
- Under the experimental conditions of this study, the NOAEL obtained was 1000 mg/kg bw/d for male and female rats after repeated oral administration of the test material in a 28 day study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.